Jiachen Li, Yingting Zuo, Lin Feng, Yutong Samuel Cai, Jian Su, Zhaohui Tong, Lirong Liang
{"title":"嗜酸性粒细胞与皮质类固醇治疗失败的关系(按 AECOPD 住院患者的吸烟情况分层","authors":"Jiachen Li, Yingting Zuo, Lin Feng, Yutong Samuel Cai, Jian Su, Zhaohui Tong, Lirong Liang","doi":"10.1136/bmjresp-2023-001634","DOIUrl":null,"url":null,"abstract":"Background Recent studies have suggested elevated blood eosinophils are independent predictors of response to corticosteroid therapy in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Smoking status has been shown to affect corticosteroid response. Whether the association between high blood eosinophils and corticosteroid treatment failure is modified by smoking has not been fully investigated so far. Objectives This study aimed to assess whether the association between high blood eosinophils and corticosteroid treatment failure is modified by smoking. Methods We included 3402 inpatients with AECOPD treated with corticosteroids at Beijing Chao-Yang Hospital from July 2013 to June 2021. Blood eosinophil counts were measured within 24 hours of admission. An eosinophil percentage ≥2% was considered as high eosinophilic. Smokers in this study were defined as current or former smokers. Treatment failure was defined as a worsening of AECOPD that led to adverse clinical outcomes or required further treatment or an extended hospital stay or hospitalisation following the exacerbation. Multivariate-adjusted logistic models were used to estimate the OR and 95% CI associated with treatment failure. Results There were 958 (28.2%) treatment failure events occurring. Patients with high eosinophils had a lower risk of treatment failure (OR 0.74, 95% CI 0.63 to 0.87) than patients with low eosinophils. Compared with never smoking and low eosinophilic group, the ORs for treatment failure were 0.70 (95% CI 0.52 to 0.96) for never smoking and high eosinophilic group, 0.82 (95% CI 0.64 to 1.05) for smoking and low eosinophilic group and 0.62 (95% CI 0.47 to 0.81) for smoking and high eosinophilic group. Furthermore, there was no significant interaction between eosinophils and smoking status in relation to treatment failure (p for interaction=0.73). Similar results were obtained from multiple secondary outcomes and subgroup analyses. Conclusion Elevated blood eosinophils are associated with a lower rate of corticosteroid treatment failure, regardless of smoking status. Smoking does not modify the association between blood eosinophil level and corticosteroid treatment failure among inpatients with AECOPD. Data are available on reasonable request. The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.","PeriodicalId":9048,"journal":{"name":"BMJ Open Respiratory Research","volume":"46 1","pages":""},"PeriodicalIF":3.6000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Association of blood eosinophils with corticosteroid treatment failure stratified by smoking status among inpatients with AECOPD\",\"authors\":\"Jiachen Li, Yingting Zuo, Lin Feng, Yutong Samuel Cai, Jian Su, Zhaohui Tong, Lirong Liang\",\"doi\":\"10.1136/bmjresp-2023-001634\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background Recent studies have suggested elevated blood eosinophils are independent predictors of response to corticosteroid therapy in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Smoking status has been shown to affect corticosteroid response. Whether the association between high blood eosinophils and corticosteroid treatment failure is modified by smoking has not been fully investigated so far. Objectives This study aimed to assess whether the association between high blood eosinophils and corticosteroid treatment failure is modified by smoking. Methods We included 3402 inpatients with AECOPD treated with corticosteroids at Beijing Chao-Yang Hospital from July 2013 to June 2021. Blood eosinophil counts were measured within 24 hours of admission. An eosinophil percentage ≥2% was considered as high eosinophilic. Smokers in this study were defined as current or former smokers. Treatment failure was defined as a worsening of AECOPD that led to adverse clinical outcomes or required further treatment or an extended hospital stay or hospitalisation following the exacerbation. Multivariate-adjusted logistic models were used to estimate the OR and 95% CI associated with treatment failure. Results There were 958 (28.2%) treatment failure events occurring. Patients with high eosinophils had a lower risk of treatment failure (OR 0.74, 95% CI 0.63 to 0.87) than patients with low eosinophils. Compared with never smoking and low eosinophilic group, the ORs for treatment failure were 0.70 (95% CI 0.52 to 0.96) for never smoking and high eosinophilic group, 0.82 (95% CI 0.64 to 1.05) for smoking and low eosinophilic group and 0.62 (95% CI 0.47 to 0.81) for smoking and high eosinophilic group. Furthermore, there was no significant interaction between eosinophils and smoking status in relation to treatment failure (p for interaction=0.73). Similar results were obtained from multiple secondary outcomes and subgroup analyses. Conclusion Elevated blood eosinophils are associated with a lower rate of corticosteroid treatment failure, regardless of smoking status. Smoking does not modify the association between blood eosinophil level and corticosteroid treatment failure among inpatients with AECOPD. Data are available on reasonable request. The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.\",\"PeriodicalId\":9048,\"journal\":{\"name\":\"BMJ Open Respiratory Research\",\"volume\":\"46 1\",\"pages\":\"\"},\"PeriodicalIF\":3.6000,\"publicationDate\":\"2024-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BMJ Open Respiratory Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1136/bmjresp-2023-001634\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"RESPIRATORY SYSTEM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMJ Open Respiratory Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/bmjresp-2023-001634","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0
摘要
背景 最近的研究表明,血液中嗜酸性粒细胞的升高是慢性阻塞性肺疾病(AECOPD)急性加重患者对皮质类固醇治疗反应的独立预测因素。吸烟状况已被证明会影响对皮质类固醇的反应。至于吸烟是否会改变高血嗜酸性粒细胞与皮质类固醇治疗失败之间的关联,迄今为止尚未进行全面研究。目的 本研究旨在评估高血嗜酸性粒细胞与皮质类固醇治疗失败之间的关系是否会因吸烟而改变。方法 我们纳入了 2013 年 7 月至 2021 年 6 月在北京朝阳医院接受皮质类固醇治疗的 3402 例 AECOPD 住院患者。在入院 24 小时内测量血液中的嗜酸性粒细胞计数。嗜酸性粒细胞百分比≥2%为高嗜酸性粒细胞。本研究中的吸烟者定义为目前或曾经吸烟者。治疗失败是指AECOPD病情恶化,导致不良临床结果,或需要进一步治疗,或在病情加重后延长住院时间或住院治疗。采用多变量调整逻辑模型估算与治疗失败相关的OR和95% CI。结果 发生了 958 例(28.2%)治疗失败事件。与嗜酸性粒细胞低的患者相比,嗜酸性粒细胞高的患者治疗失败的风险较低(OR 0.74,95% CI 0.63 至 0.87)。与从不吸烟和低嗜酸性粒细胞组相比,从不吸烟和高嗜酸性粒细胞组治疗失败的 OR 值为 0.70(95% CI 0.52 至 0.96),吸烟和低嗜酸性粒细胞组为 0.82(95% CI 0.64 至 1.05),吸烟和高嗜酸性粒细胞组为 0.62(95% CI 0.47 至 0.81)。此外,嗜酸性粒细胞与吸烟状态之间在治疗失败方面没有明显的交互作用(交互作用 p=0.73)。多个次要结果和亚组分析也得出了类似的结果。结论 无论吸烟与否,血液嗜酸性粒细胞升高与皮质类固醇治疗失败率降低有关。在 AECOPD 住院患者中,吸烟不会改变血液嗜酸性粒细胞水平与皮质类固醇治疗失败之间的关系。如有合理要求,可提供相关数据。本研究中使用和/或分析的数据集可向通讯作者索取。
Association of blood eosinophils with corticosteroid treatment failure stratified by smoking status among inpatients with AECOPD
Background Recent studies have suggested elevated blood eosinophils are independent predictors of response to corticosteroid therapy in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Smoking status has been shown to affect corticosteroid response. Whether the association between high blood eosinophils and corticosteroid treatment failure is modified by smoking has not been fully investigated so far. Objectives This study aimed to assess whether the association between high blood eosinophils and corticosteroid treatment failure is modified by smoking. Methods We included 3402 inpatients with AECOPD treated with corticosteroids at Beijing Chao-Yang Hospital from July 2013 to June 2021. Blood eosinophil counts were measured within 24 hours of admission. An eosinophil percentage ≥2% was considered as high eosinophilic. Smokers in this study were defined as current or former smokers. Treatment failure was defined as a worsening of AECOPD that led to adverse clinical outcomes or required further treatment or an extended hospital stay or hospitalisation following the exacerbation. Multivariate-adjusted logistic models were used to estimate the OR and 95% CI associated with treatment failure. Results There were 958 (28.2%) treatment failure events occurring. Patients with high eosinophils had a lower risk of treatment failure (OR 0.74, 95% CI 0.63 to 0.87) than patients with low eosinophils. Compared with never smoking and low eosinophilic group, the ORs for treatment failure were 0.70 (95% CI 0.52 to 0.96) for never smoking and high eosinophilic group, 0.82 (95% CI 0.64 to 1.05) for smoking and low eosinophilic group and 0.62 (95% CI 0.47 to 0.81) for smoking and high eosinophilic group. Furthermore, there was no significant interaction between eosinophils and smoking status in relation to treatment failure (p for interaction=0.73). Similar results were obtained from multiple secondary outcomes and subgroup analyses. Conclusion Elevated blood eosinophils are associated with a lower rate of corticosteroid treatment failure, regardless of smoking status. Smoking does not modify the association between blood eosinophil level and corticosteroid treatment failure among inpatients with AECOPD. Data are available on reasonable request. The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
期刊介绍:
BMJ Open Respiratory Research is a peer-reviewed, open access journal publishing respiratory and critical care medicine. It is the sister journal to Thorax and co-owned by the British Thoracic Society and BMJ. The journal focuses on robustness of methodology and scientific rigour with less emphasis on novelty or perceived impact. BMJ Open Respiratory Research operates a rapid review process, with continuous publication online, ensuring timely, up-to-date research is available worldwide. The journal publishes review articles and all research study types: Basic science including laboratory based experiments and animal models, Pilot studies or proof of concept, Observational studies, Study protocols, Registries, Clinical trials from phase I to multicentre randomised clinical trials, Systematic reviews and meta-analyses.